Research from West China Second University Hospital Yields New Data on Lung Cancer (Differences in medical costs among urban lung cancer patients with different health insurance schemes: a retrospective study): Oncology – Lung Cancer

2022 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Investigators discuss new findings in lung cancer. According to news originating from West China Second University Hospital by NewsRx correspondents, research stated, “Health insurance plays a significant role in reducing the financial burden for lung cancer patients. However, limited research exists regarding the differences in medical costs for lung cancer patients with different insurance schemes across different cities.”

Our news editors obtained a quote from the research from West China Second University Hospital: “We aimed to assess disparities in lung cancer patients’ costs by insurance type and city-specific insurance type. Claim data of China Urban Employees’ Basic Medical Insurance (UEBMI) and Urban Residents’ Basic Medical Insurance (URBMI) between 2010 and 2016 were employed to investigate differences in medical costs. This study primarily applied descriptive analysis and a generalized linear model with a gamma distribution and a log link. In total, 92,856 lung cancer patients with inpatient records were identified, with Renminbi (RMB) 11,276 [6322-20,850] (median [interquartile range]) medical costs for the UEBMI group and RMB 8303 [4492-14,823] for the URBMI group. Out-of-pocket (OOP) expenses for the UEBMI group was RMB 2143 [1108-4506] and RMB 2975 [1367-6275] for the URBMI group. The UEBMI group also had significantly higher drug costs, medical service costs, and medical consumable costs, compared to the URBMI group. Regarding city-specific insurances, medical costs for the UEBMI and the URBMI lung cancer patients in Shanghai were RMB 9771 [5183-16,623] and RMB 9741 [5924-16,067], respectively. In Xianyang, the medical costs for UEBMI and URBMI patients were RMB 11,398 [6880-20,648] and RMB 9853 [5370-24,674], respectively. The regression results showed that the UEBMI group had 27.31% fewer OOP expenses than the URBMI group did, while patients in Xiangyang and Xianyang had 39.53 and 35.53% fewer OOP expenses, respectively, compared to patients in Shanghai.”

According to the news editors, the research concluded: “Compared with the URBMI patients, the UEBMI lung cancer patients obtained more or even better health services and had reduced financial burden. The differences in insurances among cities were greater, compared to those among insurances within cities, and the differences in OOP expenses between cities were greater compared to those between UEBMI and URBMI. Our results called for further reform of China’s fragmented insurance schemes.”

For more information on this research see: Differences in medical costs among urban lung cancer patients with different health insurance schemes: a retrospective study. BMC Health Services Research, 2022,22(1):1-10. (BMC Health Services Research - http://bmchealthservres.biomedcentral.com). The publisher for BMC Health Services Research is BMC.

A free version of this journal article is available at https://doi.org/10.1186/s12913-022-07957-9.

Our news journalists report that additional information may be obtained by contacting Yichen Li, West China Second University Hospital, Sichuan University. Additional authors for this research include Yong Yang, Jia Yuan, Lieyu Huang, Yong Ma, Xuefeng Shi.

(Our reports deliver fact-based news of research and discoveries from around the world.)